Subtopic Deep Dive
Psilocybin Therapeutic Applications
Research Guide
What is Psilocybin Therapeutic Applications?
Psilocybin therapeutic applications involve clinical trials and neuroimaging studies evaluating psilocybin-assisted psychotherapy for treatment-resistant depression, addiction, and mood disorders.
Open-label trials show large effect sizes for psilocybin in treatment-resistant depression with sustained improvements at six months (Carhart-Harris et al., 2017, 927 citations). Meta-analyses confirm serotonergic psychedelics reduce depressive symptoms in mood disorder patients (Galvão-Coelho et al., 2021, 139 citations). Recent randomized trials test repeated psilocybin doses for depression (Rosenblat et al., 2024, 73 citations). Over 1,600 citations across 10 key papers since 2017.
Why It Matters
Psilocybin trials offer treatments for treatment-resistant depression amid mental health crises (Carhart-Harris et al., 2017). Meta-analyses support efficacy for mood disorders, addressing unmet needs in depression care (Galvão-Coelho et al., 2021). Integration challenges post-retreat highlight needs for psychotherapy protocols (Lutkajtis and Evans, 2023). Expectancy effects in trials inform blinded study designs (Butler et al., 2022). Regulatory paths via expanded access enable palliative use (Byock, 2018).
Key Research Challenges
Blinding and Expectancy Bias
Placebo-controlled psychedelic trials face unblinding due to intense subjective effects, inflating expectancy biases (Butler et al., 2022, 77 citations). This challenges efficacy claims in early-phase research. Meta-analyses note inconsistent blinding assessments across studies (Galvão-Coelho et al., 2021).
Post-Treatment Integration
Participants report difficulties integrating psilocybin experiences into daily life after retreats (Lutkajtis and Evans, 2023, 54 citations). Lack of standardized protocols hinders sustained benefits. Informed consent must address transformative effects (Jacobs, 2023, 53 citations).
Regulatory and Scalability Barriers
Political and industry issues limit psychedelic clinical adoption despite evidence (Byock, 2018, 162 citations). Repeated dosing trials require scalable psychotherapy models (Rosenblat et al., 2024). Variability in non-clinical use patterns complicates therapeutic standardization (Pestana et al., 2020).
Essential Papers
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Robin Carhart‐Harris, Mark Bolstridge, Camilla Day et al. · 2017 · Psychopharmacology · 927 citations
Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocy...
Potential Therapeutic Effects of Psilocybin
Matthew W. Johnson, Roland R. Griffiths · 2017 · Neurotherapeutics · 287 citations
Taking Psychedelics Seriously
Ira Byock · 2018 · Journal of Palliative Medicine · 162 citations
Even with an expanding evidence base confirming safety and benefits, political, regulatory, and industry issues impose challenges to the legitimate use of psychedelics. The federal expanded access ...
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
Nicole Leite Galvão‐Coelho, Wolfgang Marx, Maria Gonzalez et al. · 2021 · Psychopharmacology · 139 citations
Abstract Rationale Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic tr...
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Matthew Butler, Luke A. Jelen, James Rucker · 2022 · Psychopharmacology · 77 citations
Abstract Modern psychedelic research remains in an early phase, and the eventual introduction of psychedelics into clinical practice remains in doubt. In this piece, we discuss the role of blinding...
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle et al. · 2024 · Med · 73 citations
Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands
Anna Lutkajtis, Jules Evans · 2023 · Journal of Psychedelic Studies · 54 citations
Abstract This article reports on integration challenges that were experienced by nine individuals who attended a three-day legal psilocybin truffle retreat in the Netherlands. The study employed a ...
Reading Guide
Foundational Papers
No pre-2015 papers available; start with Carhart-Harris et al. (2017) for initial open-label depression trial establishing large effect sizes and tolerability.
Recent Advances
Rosenblat et al. (2024) for repeated dosing RCT; Lutkajtis and Evans (2023) for integration challenges; Butler et al. (2022) for expectancy in trials.
Core Methods
Psilocybin sessions with psychological support, Hamilton Depression Rating Scale assessments, meta-analysis of serotonergic effects, phenomenological interviews.
How PapersFlow Helps You Research Psilocybin Therapeutic Applications
Discover & Search
Research Agent uses searchPapers and exaSearch to find psilocybin depression trials, then citationGraph on Carhart-Harris et al. (2017) reveals 927 citing papers on follow-up efficacy. findSimilarPapers expands to meta-analyses like Galvão-Coelho et al. (2021).
Analyze & Verify
Analysis Agent applies readPaperContent to extract effect sizes from Carhart-Harris et al. (2017), verifies meta-analysis claims via verifyResponse (CoVe), and runs PythonAnalysis with pandas to aggregate depression scores across Galvão-Coelho et al. (2021) and Rosenblat et al. (2024). GRADE grading scores evidence as moderate for open-label trials.
Synthesize & Write
Synthesis Agent detects gaps in integration research post-Lutkajtis and Evans (2023), flags contradictions in expectancy biases (Butler et al., 2022). Writing Agent uses latexEditText for review drafting, latexSyncCitations for 10 papers, and latexCompile for publication-ready PDF; exportMermaid visualizes trial flowcharts.
Use Cases
"Run meta-analysis of psilocybin effect sizes on depression scores from trials."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on Carhart-Harris 2017 and Galvão-Coelho 2021) → researcher gets CSV of pooled effect sizes with p-values.
"Draft LaTeX review on psilocybin for treatment-resistant depression."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Carhart-Harris 2017 et al.) + latexCompile → researcher gets compiled PDF with figures.
"Find code for analyzing psilocybin neuroimaging data from similar papers."
Research Agent → findSimilarPapers → Code Discovery (paperExtractUrls → paperFindGithubRepo → githubRepoInspect) → researcher gets inspected GitHub repo with fMRI analysis scripts.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (psilocybin depression) → citationGraph → DeepScan (7-step verification on 50+ papers like Carhart-Harris 2017) → structured report with GRADE scores. Theorizer generates hypotheses on expectancy mitigation from Butler et al. (2022) and Rosenblat et al. (2024). Chain-of-Verification (CoVe) ensures hallucination-free synthesis across integration papers.
Frequently Asked Questions
What defines psilocybin therapeutic applications?
Clinical trials using psilocybin with psychotherapy for depression and addiction, tracked via neuroimaging of mood networks (Carhart-Harris et al., 2017).
What are key methods in psilocybin research?
Open-label and randomized trials with psychological support, repeated dosing, and meta-analyses of mood outcomes (Rosenblat et al., 2024; Galvão-Coelho et al., 2021).
What are major papers?
Carhart-Harris et al. (2017, 927 citations) on 6-month depression follow-up; Johnson and Griffiths (2017, 287 citations) on therapeutic effects.
What open problems exist?
Blinding in trials (Butler et al., 2022), integration post-treatment (Lutkajtis and Evans, 2023), and regulatory scalability (Byock, 2018).
Research Diverse academic research themes with AI
PapersFlow provides specialized AI tools for Decision Sciences researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Economics & Business use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Psilocybin Therapeutic Applications with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Decision Sciences researchers
Part of the Diverse academic research themes Research Guide